Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
| ▸ | GABRD | O14764 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.53 |
| ▸ | GABRE | P78334 | 1/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390410 | 1.00 | MAPT (0.59) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL28612277 | 0.98 | MAPT (0.57) | MAPTALDH1A1TDP1HPGDGABRP | |
| Lithium Ion SCHEMBL31133341 | 0.98 | MAPT (0.57) | MAPTALDH1A1TDP1HPGDGABRP | |
| Hydrochloric Acid SCHEMBL548656 | 0.98 | MAPT (0.57) | MAPTALDH1A1TDP1HPGDGABRP | |
| Pyridine SCHEMBL18550491 | 0.91 | MAPT (0.55) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL1892689 | 0.88 | GABRP (0.51) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL21819460 | 0.87 | MAPT (0.47) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL27293915 | 0.84 | MAPT (0.56) | MAPTALDH1A1TDP1HPGDNPC1 | |
| SCHEMBL31175233 | 0.83 | TDP1 (0.52) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL6531550 | 0.83 | MAPT (0.54) | MAPTALDH1A1TDP1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109706453-B | Application of benzopyrazine compound in copper surface roughening and composition containing benzopyrazine compound for copper surface roughening | 广东东硕科技有限公司 | 2021-02-23 | — | — | CN | claimed |
| CN-109912574-A | A kind of pyrazoline class compound and its preparation method and application | 合肥工业大学 | 2019-06-21 | — | — | CN | claimed |
| CN-108289912-A | The immunocyte and application thereof of immunity or inhibitive ability of immunity cell factor resistance with raising | 先天肿瘤免疫公司 | 2018-07-17 | — | — | CN | claimed |
| CN-107820496-A | For treating and preventing the hepatitis b virus infected new formic acid derivates of 4 oxo pyridine of Fourth Ring 3 | 豪夫迈·罗氏有限公司 | 2018-03-20 | — | — | CN | claimed |
| CN-107454900-A | Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer | 蒙彼利埃大学 | 2017-12-08 | — | — | CN | claimed |
| CN-102656163-B | Suppress the heterogeneous ring compound of PASK | BIOENERGENIX (US) | 2016-01-13 | — | — | CN | claimed |
| CN-103619846-A | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives | JANSSEN PHARMACEUTICA NV | 2014-03-05 | — | — | CN | claimed |
| US-8404679-B2 | Pyrrolidine derivatives as NK2 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | claimed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | claimed |
| US-20120208803-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | BISSANTZ CATERINA (FR) | 2012-08-16 | — | — | US | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| WO-2008122510-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | claimed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| WO-2008050200-A1 | OXADIAZOLE COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-02 | — | — | WO | claimed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | claimed |
| EP-1758892-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123719-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-12-29 | — | — | WO | claimed |
| WO-1999009845-A1 | IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | MAPT 4842/4885ALDH1A1 834/4885TDP1 4802/4885 |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, PTK2B, SRC | MAPT 1088/4885ALDH1A1 4552/4885TDP1 900/4885 |
| US-20120208803-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | TACR2, PRLHR, AVPR2 | MAPT 597/4885ALDH1A1 1125/4885TDP1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.